About
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada. Address: 275 Armand-Frappier Boulevard, Laval, QC, Canada, H7V 4A7 Read Less
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Ph ...Read More
Company Website : https://www.bellushealth.com
Address : 275 Armand-Frappier Boulevard, Laval, QC, Canada, H7V 4A7
Employees : 40
Fiscal Year End : December
Currency:
CAD
Country :
Canada